Standard Vs Supralabial Bispectral Index Scores
Launched by RAJIV GANDHI CANCER INSTITUTE & RESEARCH CENTER, INDIA · Jan 31, 2020
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
Consequences of intraoperative awareness could be hemodynamic disturbances, long-lasting psychological problem and medicolegal issues. Bispectral index (BIS) is the most widely used noninvasive method to estimate level of consciousness. Complex electroencephalography (EEG) parameter that converts raw EEG data from the frontal cortex into a single number between 100 (fully awake) and 0 (isoelectric EEG).
The BIS sensor is a single adhesive strip placed across the forehead. This position can be problematic in certain surgical procedures involving a neurosurgery, surgery involving fronto-temp...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age group: 18-65 yrs
- • ASA status: 1-3
- • Use of endotracheal tube for securing the airway
- Exclusion Criteria:
- • Facial deformity : scars, cleft lip, mole etc
- • Presence of beard and moustache
- • Use of supraglottic device
- • Patient under regional anaesthesia
About Rajiv Gandhi Cancer Institute & Research Center, India
The Rajiv Gandhi Cancer Institute & Research Center (RGCI&RC) in India is a leading institution dedicated to the comprehensive care and advanced research in oncology. Renowned for its commitment to providing cutting-edge cancer treatment, RGCI&RC combines clinical excellence with innovative research initiatives aimed at improving patient outcomes. The institute boasts state-of-the-art facilities and a multidisciplinary team of experts who collaborate to conduct clinical trials, explore new therapies, and enhance the understanding of cancer. RGCI&RC's mission is to advance cancer care through rigorous scientific inquiry and compassionate patient management, positioning itself as a pivotal player in the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, Delhi, India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials